tNOX, an alternative target to COX-2 to explain the anticancer activities of non-steroidal anti-inflammatory drugs (NSAIDS)
- 168 Downloads
Our work has identified a cancer-specific, cell surface and growth-related quinol oxidase with both NADH oxidase and protein disulfide-thiol interchange activities, a member of the ECTO-NOX protein family designated tNOX. We provide evidence for tNOX as an alternative drug target to COX-2 to explain the anticancer activity of COX inhibitors. Non-steroidal anti-inflammatory drugs (NSAIDS), piroxicam, aspirin, ibuprofen, naproxen and celecoxib all specifically inhibited tNOX activity of HeLa (human cervical carcinoma) and BT-20 (human mammary carcinoma) cells (IC50 in the nanomolar range) without effect on ECTO-NOX activities of non-cancer MCF-10A mammary epithelial cells. With cancer cells, rofecoxib was less effective and two NSAIDS selective for COX-1 were without effect in inhibiting NOX activity. The IC50 for inhibition of tNOX activity of HeLa cells and the IC50 for inhibition of growth of HeLa cells in culture were closely correlated. The findings provide evidence for a new drug target to account for anticancer effects of NSAIDS that occur independent of COX-2.
Keywordsaspirin cancer celecoxib cyclooxygenase ECTO-NOX hydroquinone (NADH) oxidase: tNOX NADH oxidase non-steroidal anti-inflammatory drugs (NSAIDS) rofecoxib tumor associated hydroquinone (NADH) oxidase
Unable to display preview. Download preview PDF.
- 7.Kazanov D, Dvory-Sobol H, Pick M, Liberman E, Strier L, Choen-Noyman E, Deutsch V, Kunik T, Arber N: Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. Clin Can Res 10: 267–271, 2004Google Scholar
- 8.Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ: Celecoxib inhibits prostate cancer growth: Evidence of a cyclooxygenase-2-independent mechanism. Clin Can Res 11: 1999–2007, 2005Google Scholar
- 10.Morré DJ, Morré DM: Cell surface NADH oxidase (ECTO-NOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative diseases. Free Rad Res 37: 759–808, 2003Google Scholar
- 12.Morré DJ: NADH oxidase: a multifunctional ectoprotein of the eukaryotic cell surface. In: H. Asard, A. Bérczi, R. Caubergs (eds). Plasma membrane redox systems and their role in biological stress and disease. Kluwer Academic Publishers, Dordrecht, The Netherlands, 1998 pp. 121–156Google Scholar
- 16.Morré DJ, Chueh P-J, Morré DM: Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture. Proc Natl Acad Sci USA 92: 1821–1835, 1995Google Scholar
- 17.North GL: Celecoxib as adjunctive therapy for treatment of colorectal cancer. An Pharmacother 35: 1638–1643, 2001Google Scholar
- 19.Chueh P-J, Wu L-Y, Morré DM, Morré DJ: tNOX is both necessary and sufficient as a cellular target for the anticancer actions of capsaicin and the green tea catechin (−) epigallocatechin gallate. BioFactors 20: 249–263, 2004Google Scholar
- 21.Morré DM, Morré DJ: Mechanism of killing of HeLa cells by the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N′-(4-chlorophenyl)urea (LY181984). Protoplasma 184: 188–195, 1995Google Scholar
- 22.Tang X, Tian Z, Chueh P-J, Chen S, Morré DM, Morré DJ: Alternative splicing as the basis for specific localization of tNOX, a unique hydroquinone (NADH) oxidase, to the cancer cell surface. In preparationGoogle Scholar
- 23.Morré DJ, Morré DM, Su H, Cooper R, Chang J, Janle EM: Tea catechin synergies in inhibition of cancer cell proliferation and of a cancer specific cell surface oxidase (ECTO-NOX). Pharmcol Toxicol 92: 234–241, 2003Google Scholar
- 33.Bosett C, Gallus S, La Vecchia C: Aspirin and cancer risk: an update to 2001. Eur J Cancer Prev 11: 535–542, 2002Google Scholar